Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

AMARA PAIN & SPINE PLLC

NPI: 1417371154 · CHARLOTTE, NC 28226 · Pain Medicine (Anesthesiology) Physician · NPI assigned 02/18/2014

$1.17M
Total Medicaid Paid
44,069
Total Claims
25,392
Beneficiary Records
15
Codes Billed
2018-01
First Month
2024-12
Last Month

Provider Details

Authorized OfficialAMARA, ASHVIN (OWNER)
NPI Enumeration Date02/18/2014

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 4,237 $99K
2019 5,704 $167K
2020 5,612 $198K
2021 7,740 $224K
2022 8,621 $160K
2023 6,359 $139K
2024 5,796 $182K

Billing Codes

CodeDescriptionClaimsBene. RecordsTotal Paid
99214 Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 24,375 14,533 $560K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 2,933 1,708 $276K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 10,081 5,986 $199K
27096 1,283 698 $45K
99204 Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity 639 346 $26K
77002 1,898 754 $16K
20610 1,506 556 $15K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 70 63 $9K
20553 550 280 $6K
99213 Office or other outpatient visit for the evaluation and management of an established patient, low complexity 230 162 $5K
99443 287 156 $5K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 102 62 $3K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 47 39 $3K
99442 29 19 $315.28
99441 39 30 $282.93